Bernardo Queralt

867 total citations
23 papers, 675 citations indexed

About

Bernardo Queralt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Bernardo Queralt has authored 23 papers receiving a total of 675 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 4 papers in Hepatology. Recurrent topics in Bernardo Queralt's work include Colorectal Cancer Treatments and Studies (17 papers), Gastric Cancer Management and Outcomes (10 papers) and Cancer Treatment and Pharmacology (8 papers). Bernardo Queralt is often cited by papers focused on Colorectal Cancer Treatments and Studies (17 papers), Gastric Cancer Management and Outcomes (10 papers) and Cancer Treatment and Pharmacology (8 papers). Bernardo Queralt collaborates with scholars based in Spain, United States and Palestinian Territory. Bernardo Queralt's co-authors include Javier A. Menéndez, Joaquim Bosch‐Barrera, Javier Sastre, Fernando Rivera, Enrique Aranda, Joan Maurel, Josep Tabernero, Eduardo Díaz‐Rubio, Manuel Chaves-Conde and Encarnación González‐Flores and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Bernardo Queralt

23 papers receiving 667 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bernardo Queralt Spain 13 487 269 172 121 102 23 675
Elena Ongaro Italy 15 495 1.0× 304 1.1× 273 1.6× 98 0.8× 153 1.5× 38 878
Colin Germond Canada 12 500 1.0× 161 0.6× 214 1.2× 89 0.7× 54 0.5× 21 794
Kalliopi Andrikou Italy 16 534 1.1× 287 1.1× 189 1.1× 85 0.7× 123 1.2× 54 837
Ling Gao United States 15 343 0.7× 317 1.2× 207 1.2× 39 0.3× 48 0.5× 46 633
Weiguo Su China 15 357 0.7× 335 1.2× 225 1.3× 119 1.0× 114 1.1× 65 699
Ayako Mizota Japan 9 387 0.8× 260 1.0× 111 0.6× 45 0.4× 187 1.8× 16 589
Annett Maderer Germany 12 254 0.5× 161 0.6× 96 0.6× 49 0.4× 77 0.8× 25 440
Masaya Nishino Japan 12 299 0.6× 404 1.5× 301 1.8× 48 0.4× 61 0.6× 46 668
Satoshi Yuki Japan 19 819 1.7× 435 1.6× 201 1.2× 109 0.9× 237 2.3× 129 1.1k
Tsai‐Sheng Yang Taiwan 12 315 0.6× 148 0.6× 194 1.1× 308 2.5× 160 1.6× 37 733

Countries citing papers authored by Bernardo Queralt

Since Specialization
Citations

This map shows the geographic impact of Bernardo Queralt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernardo Queralt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernardo Queralt more than expected).

Fields of papers citing papers by Bernardo Queralt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernardo Queralt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernardo Queralt. The network helps show where Bernardo Queralt may publish in the future.

Co-authorship network of co-authors of Bernardo Queralt

This figure shows the co-authorship network connecting the top 25 collaborators of Bernardo Queralt. A scholar is included among the top collaborators of Bernardo Queralt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernardo Queralt. Bernardo Queralt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Martini, Giulia, Iosune Baraibar, Guillermo Villacampa, et al.. (2020). Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) metastatic colorectal cancer (mCRC) treated with doublet or triplet targeted therapy.. Journal of Clinical Oncology. 38(15_suppl). 4112–4112. 4 indexed citations
2.
Cuyàs, Elisabet, Bernardo Queralt, Begoña Martı́n-Castillo, Joaquim Bosch‐Barrera, & Javier A. Menéndez. (2017). EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells. Oncology Reports. 38(1). 263–270. 12 indexed citations
3.
Alsina, María, Fernando Rivera, Francisco Javier Ramos, et al.. (2017). A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. Targeted Oncology. 13(1). 69–78. 1 indexed citations
4.
Bosch‐Barrera, Joaquim, Bernardo Queralt, & Javier A. Menéndez. (2017). Targeting STAT3 with silibinin to improve cancer therapeutics. Cancer Treatment Reviews. 58. 61–69. 97 indexed citations
5.
Queralt, Bernardo, Elisabet Cuyàs, Joaquim Bosch‐Barrera, et al.. (2016). Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer. Oncotarget. 7(50). 82185–82199. 17 indexed citations
6.
García‐Alfonso, Pilar, Manuel Chaves-Conde, Andrés Muñoz, et al.. (2015). Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. BMC Cancer. 15(1). 327–327. 10 indexed citations
7.
Cazador, Antonio Codina, Cristina Oliveras‐Ferraros, Sílvia Cufí, et al.. (2014). Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics. Oncotarget. 5(7). 1942–1954. 11 indexed citations
8.
Alfonso, Pilar, Manuel Chaves-Conde, Andrés Muñoz, et al.. (2013). Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in metastatic colorectal cancer (mCRC) patients.. Journal of Clinical Oncology. 31(4_suppl). 501–501. 1 indexed citations
9.
Vera, Ruth, María Luisa Gómez Dorronsoro, Santiago López‐Ben, et al.. (2013). Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab. Clinical & Translational Oncology. 16(8). 739–745. 18 indexed citations
10.
Figueras, Joan, et al.. (2012). Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma. Clinical & Translational Oncology. 15(6). 460–466. 6 indexed citations
11.
Gallego, Rosa, Marta Martín-Richard, Carles Pericay, et al.. (2012). Phase II study of oxaliplatin and sorafenib in advanced gastric cancer after failure of cisplatin-fluoropyrimidine-based (PF) treatment.. Journal of Clinical Oncology. 30(15_suppl). 4079–4079. 4 indexed citations
12.
Oliveras‐Ferraros, Cristina, Sílvia Cufí, Bernardo Queralt, et al.. (2012). Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. British Journal of Cancer. 106(8). 1406–1414. 39 indexed citations
13.
14.
Vera, Ruth, Joan Figueras, María Luisa Gómez Dorronsoro, et al.. (2012). Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab: Updated findings.. Journal of Clinical Oncology. 30(15_suppl). e14120–e14120. 1 indexed citations
15.
Grávalos, Cristina, Carlos Gómez-Martín, Fernando Rivera, et al.. (2011). Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clinical & Translational Oncology. 13(3). 179–184. 60 indexed citations
16.
Oliveras‐Ferraros, Cristina, Alejandro Vázquez‐Martín, Sílvia Cufí, et al.. (2010). Stem cell property epithelial‐to‐mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild‐type tumor cells. Journal of Cellular Biochemistry. 112(1). 10–29. 38 indexed citations
17.
Oliveras‐Ferraros, Cristina, Anna Massaguer, Alejandro Vázquez‐Martín, et al.. (2010). Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells. Investigational New Drugs. 30(2). 846–852. 12 indexed citations
18.
Sastre, Javier, Enrique Aranda, Bartomeu Massutí, et al.. (2008). Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study. Critical Reviews in Oncology/Hematology. 70(2). 134–144. 40 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elena Ongaro Breakdown of academic impact, for papers by Colin Germond Breakdown of academic impact, for papers by Kalliopi Andrikou Breakdown of academic impact, for papers by Ling Gao Breakdown of academic impact, for papers by Weiguo Su Breakdown of academic impact, for papers by Ayako Mizota Breakdown of academic impact, for papers by Annett Maderer Breakdown of academic impact, for papers by Masaya Nishino Breakdown of academic impact, for papers by Satoshi Yuki Breakdown of academic impact, for papers by Tsai‐Sheng Yang
Rankless by CCL
2026